​Mission Street and One Nucleus invite you to a panel discussion followed by networking.

​AI dominates the sector’s narrative, but this session goes beyond the headlines. We’ll explore the real‑world challenges and benefits of AI across the life sciences value chain, from early‑stage innovation and target discovery to clinical development, regulatory pathways and commercialisation.

​We’ll also examine how investors are viewing AI‑enabled companies in the current landscape, including what differentiates genuine value creation from inflated expectations. The aim is to give attendees a grounded, practical understanding of AI’s evolving role and what it means for the future of UK life sciences.